Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer
View Patent ↗Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.
1. A combination comprising an inhibitor of the Src family of non-receptor tyrosine kinases selected from the group consisting of dasatinib, and AZD0530, or a pharmaceutically-acceptable salt thereof, and an aurora kinase inhibitor selected from the group consisting of C1368, PHA-680632, MLN8237, and Aurora A kinase inhibitory siRNA, or a pharmaceutically acceptable salt thereof for use in the synergistic treatment of colorectal or ovarian cancer.
2. A combination as claimed in claim 1 wherein the Src inhibitor is dasatinib and said Aurora kinase inhibitor is C1368.
3. A combination as claimed in claim 1 wherein the Src inhibitor is dasatinib and said Aurora kinase inhibitor is PHA-680632.
4. A combination as claimed in claim 1 wherein the Src inhibitor is dasatinib and the Aurora kinase inhibitor is MLN8237.
5. A pharmaceutical composition for use in the synergistic treatment or prophylaxis of cancer comprising the combination of claim 1 in a pharmaceutically-acceptable excipient or carrier.
6. A method for the synergistic treatment of colorectal or ovarian cancer in a patient in need of such treatment, comprising the administration of an effective amounts of the combination of claim 1 .
7. The method of claim 6 , wherein said aurora kinase inhibitor is selected from the group consisting of C1368, PHA-680632, MLN8237, and Aurora A kinase inhibitory siRNA.
8. The method of claim 6 , wherein said src inhibitor is selected from the group consisting of dasatinib and AZD0530.
9. The method of claim 6 further comprising administration of an effective amount of at least one anti-cancer agent.
10. The method of claim 6 , wherein said agents are administered simultaneously.
11. The method of claim 6 , wherein said agents are administered sequentially.
12. The method of claim 6 , wherein said patient has colorectal cancer and the Src inhibitor is dasatinib and said Aurora kinase inhibitor is PHA-680632.
13. The method of claim 6 , wherein said patient has ovarian cancer and the Src inhibitor is dasatinib and said Aurora kinase inhibitor is PHA-680632.